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Purpose: Small airway changes and dysfunction contribute importantly to airway obstruction 
in chronic obstructive pulmonary disease (COPD), which is currently treated with inhaled 
corticosteroids (ICS) and long-acting bronchodilators at Global initiative for Obstructive Lung 
Disease (GOLD) grades 2–4. This retrospective matched cohort analysis compared effective-
ness of a representative small-particle ICS (extrafine beclomethasone) and larger-particle ICS 
(fluticasone) in primary care patients with COPD.
Patients and methods: Smokers and ex-smokers with COPD $40 years old initiating or 
stepping-up their dose of extrafine beclomethasone or fluticasone were matched 1:1 for demo-
graphic characteristics, index prescription year, concomitant therapies, and disease severity 
during 1 baseline year. During 2 subsequent years, we evaluated treatment change and COPD 
exacerbations, defined as emergency care/hospitalization for COPD, acute oral corticosteroids, 
or antibiotics for lower respiratory tract infection.
Results: Mean patient age was 67 years, 57%–60% being male. For both initiation (n=334:334) 
and step-up (n=189:189) patients, exacerbation rates were comparable between extrafine 
beclomethasone and fluticasone cohorts during the 2 year outcome period. Odds of treatment 
stability (no exacerbation or treatment change) were significantly greater for patients initiating 
extrafine beclomethasone compared with fluticasone (adjusted odds ratio 2.50; 95% confidence 
interval, 1.32–4.73). Median ICS dose exposure during 2 outcome years was significantly lower 
(P,0.001) for extrafine beclomethasone than fluticasone cohorts (315 µg/day versus 436 µg/day 
for initiation, 438 µg/day versus 534 µg/day for step-up patients).
Conclusion: We observed that small-particle ICS at significantly lower doses had compa-
rable effects on exacerbation rates as larger-particle ICS at higher doses, whereas initiation 
of small-particle ICS was associated with better odds of treatment stability during 2-years’ 
follow-up.
Keywords: COPD exacerbation, extrafine particle, matched cohort analysis, real life, 
small airways
Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder char-
acterized by chronic inflammation in airway walls and lung tissue, dysfunctional 
repair and defense mechanisms, excessive mucus production, and changes in the 
small peripheral airways.1,2 These changes include thickening of small airway walls, 
loss of elasticity, airway obstruction, and accompanying emphysema.3–5 A recent 
study found that loss of functional small airways may precede the development of 
emphysema in COPD and thus the small airways may constitute an appropriate 
target for treatment.6,7
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Consensus practice guidelines for COPD recommend the 
use of inhaled corticosteroids (ICS) together with inhaled 
long-acting bronchodilators for patients at high risk of 
exacerbations, ie, with either forced expiratory volume in 
1 second (FEV
1
) ,50% predicted or a history of repeated 
 exacerbations.1 In randomized controlled trials, ICS reduce 
COPD exacerbations but are associated with a slight increase 
in risk of pneumonia.1,8–10 In clinical practice, different from 
current guideline recommendations, ICS monotherapy, usu-
ally with larger-particle ICS, is still being used for treatment 
of COPD.11–13
Because COPD starts in the small airways, a pharma-
cological approach targeting the small airways with small-
particle ICS might be beneficial. It may, however, be difficult 
to capture benefits related to small particle size in randomized 
controlled trials, which usually recruit selected patients who 
are cared for in a controlled context. Possible benefits might 
be more evident in real-life patients, whose adherence is often 
suboptimal and who may have COPD associated with other 
diseases, for example, asthma-COPD overlap syndrome.1 
The aim of this retrospective observational study was to 
compare the effectiveness of a representative small-particle 
ICS, extrafine beclomethasone,14–16 and a larger-particle-size 
ICS, fluticasone, in a broad, real-life primary care population 
of patients with COPD. Our hypothesis was that treatment 
with small-particle ICS would be associated with improved 
management and control of COPD, as compared with larger-
particle ICS, because of better deposition throughout the 
lungs and small airways.
Methods
study design and patients
We performed retrospective matched cohort analyses using 
de-identified patient information (1996–2010) from .450 
primary care practices throughout the UK subscribing 
to the General Practice Research Database (now in the 
Clinical Practice Research Datalink)17 and approximately 
300 practices subscribing to the Optimum Patient Care 
Research  Database.18 These two large electronic datasets, 
described in detail elsewhere,17–21 are frequently used for 
observational research. Patient characteristics were cross-
referenced between the two datasets to avoid duplication 
of individuals.
The two analyses examined patients prescribed their first 
ICS treatment (initiation sample) and those prescribed an 
increase in ICS dose (step-up sample) for COPD as either 
extrafine beclomethasone (Qvar; Teva Pharmaceuticals, 
Petach Tikva, Israel) or a commonly prescribed large-particle 
ICS, fluticasone (Flixotide; GlaxoSmithKline plc, London, 
UK), by pressurized metered-dose inhaler. We included 
male and female patients, $40 years old at the time of the 
index study prescription (index date), who had: 1) a diag-
nostic code for COPD, and 2) two or more prescriptions for 
COPD at different time points during the preceding year 
(baseline). The baseline year COPD prescriptions could be 
for any combination of the following: short-acting β
2
-agonist 
(SABA), long-acting β
2
-agonist (LABA), short-acting 
muscarinic antagonist (SAMA), long-acting muscarinic 
antagonist (LAMA), theophylline, and, for patients in the 
step-up sample only, including an ICS. The diagnostic code 
for COPD could be recorded at any time relative to the index 
date ICS prescription. Eligible patients had to be registered 
at the same general practice for at least 3 consecutive years, 
including 1 year before (baseline year) and 2 years after the 
index date (outcome period).
In practice COPD can be associated with or misdiagnosed 
as asthma; therefore, eligible patients could also have had an 
asthma diagnostic code but only if recorded for the first time 
after 40 years of age. Patients were excluded if they had a coded 
diagnosis pre-40-years for asthma or at any time for any chronic 
respiratory disease other than COPD (exclusions listed in 
Table S1). In addition, during the matching process (see below), 
we excluded non-smokers and patients without spirometric 
evidence of COPD (ie, without post-bronchodilator ratio of 
FEV
1
 to forced vital capacity [FVC] [FEV
1
/FVC] ,0.7).
Outcome measures
Exacerbation rate and odds of COPD treatment success were 
the two coprimary effectiveness measures. An exacerbation 
was defined as the occurrence of any one of the following: 
acute use of oral corticosteroids; unscheduled hospital admis-
sion or emergency department (ED) attendance for COPD 
or respiratory-related event; lower respiratory tract infection 
treated with antibiotics; or prescription for antibiotics with 
a lower respiratory database code within a ±5 day window. 
The absence of an exacerbation during the outcome period 
defined COPD treatment success.
Secondary effectiveness measures included the time 
to first exacerbation and treatment stability, defined as no 
treatment change plus no exacerbation. Treatment change 
was defined as an increase in ICS dose (of $50%) and/or 
additional therapy (new since baseline year). Other outcomes 
examined included the hospitalization rate for lower respira-
tory causes; mortality rate after the study; oral candidiasis 
(coded diagnosis or therapy, namely, oral antifungal prescrip-
tions); and two definitions of pneumonia: 1) unconfirmed 
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cases with coded pneumonia diagnosis, and 2) pneumonia 
confirmed by chest radiograph or hospitalization within 
1 month of diagnosis code. All outcome measures were 
derived from GP-provided Read codes in the electronic 
databases.
All ICS doses were standardized to equivalency with 
extrafine beclomethasone doses for the analyses, using a 1:1 
ratio for extrafine beclomethasone and all fluticasone pro-
pionate formulations, and for both the latter a 1:2 dose ratio 
relative to budesonide and larger-particle  chlorofluorocarbon- 
or hydrofluoroalkane-beclomethasone (Clenil Modulite; 
Chiesi Ltd, Cheadle, UK). The mean daily ICS dose exposure 
during baseline and outcome years was calculated as the 
dispensed amount divided by 365 (baseline year) or 730 
(outcome period).
statistical analysis
We conducted a matched cohort analysis because the explor-
atory analysis found baseline differences between treatment 
cohorts in both initiation and step-up samples. Unmatched 
patients prescribed extrafine beclomethasone tended to be 
slightly older and to have fewer baseline exacerbations than 
those in the fluticasone cohorts. Most importantly, the index 
date, which was later for extrafine beclomethasone cohorts, 
was a strongly confounding variable because of trends over 
time for earlier COPD diagnosis and treatment.  Hospitalization 
and mortality rates were significantly lower, and changes in 
therapy significantly more likely, with later index dates.
Therefore, to eliminate these and minimize other base-
line differences between treatment cohorts, we matched 
in 1:1 ratio on the following criteria: sex; age (±5 years); 
number of baseline year COPD exacerbations (0, 1, $2); 
year of index prescription (±1 year for the initiation 
sample and ±2 years for the step-up sample); and baseline 
therapy (categorized as a) SABA/SAMA/SABA + SAMA; 
b) LABA ± SABA ± SAMA; c) LAMA ± SABA ± SAMA; 
d) LABA + LAMA ± SABA ± SAMA, and e) other). In 
addition, for the step-up sample, we matched on mean daily 
ICS dose exposure during baseline (categorized as 0–250, 
251–500, and .500 µg/day). Finally, we matched on smok-
ing status; confirmation of COPD ever via post-bronchodila-
tor FEV
1
/FVC ratio ,0.7; and age at first asthma diagnosis 
(,40 years old or $40 years old/no asthma diagnosis) as a 
means of subsequently excluding – without losing matched 
groupings – all non-smokers, patients without confirmed 
COPD, and patients with asthma diagnosed before age 40.
Summary statistics were produced for all baseline and 
outcome variables. For patients with available FEV
1
 values, 
the Global initiative for Obstructive Lung Disease (GOLD) 
grade of severity of airflow limitation was determined.22 We 
compared baseline characteristics and unadjusted outcome 
variables for matched cohorts using conditional logistic 
regression, categorizing heavily skewed data. The list of 
potential confounders considered for the adjusted analy-
ses included those differing between treatment cohorts at 
baseline (P,0.10) and variables predictive (P,0.05) of 
each outcome variable in multivariate analyses (Table S2). 
Pearson and Spearman correlation coefficients were applied, 
together with clinical interpretation, to eliminate variables 
presenting collinearity issues in the regression modeling 
of outcomes.
We used a conditional Poisson regression model to 
calculate adjusted relative rates of exacerbations and of oral 
candidiasis. The adjusted odds of achieving COPD treatment 
success and treatment stability, and of having a treatment 
change, were compared between cohorts using conditional 
binary logistic regression models. A Cox proportional hazards 
model, adjusted for baseline confounders, was used to exam-
ine the time to first exacerbation and post-study  mortality. 
(Patients had to be alive during the full 2 year outcome period 
to be eligible for the study). To account for multiple compari-
sons, we controlled for false discovery rate if more than one 
of the co-primary endpoints were significant.
The composite outcome measures and analyses were 
prespecified according to standard operating procedures of 
the research group.23 All analyses were carried out using 
IBM SPSS Statistics version 19 (IBM Corporation, Armonk, 
NY, USA), SAS version 9.2 (SAS Institute Inc., Cary, NC, 
USA), and Microsoft Excel 2007 (Microsoft Corporation, 
Redmond, WA, USA). We defined statistically significant 
results as P,0.05.
Results
Patient identification in the datasets and subsequent matching 
of 384 patients in each initiation cohort, and 189 patients in 
each step-up cohort, are depicted in Figures S1 and S2.
Initiation sample
At baseline, the clinical characteristics of patients in extrafine 
beclomethasone and fluticasone cohorts were similar 
(Tables 1 and S3). Approximately 60% of patients were male, 
and the mean age was 67 years. There were several significant 
differences between cohorts (eg, in index prescription date, 
cardiac disease diagnosis, and use of some drugs), but these 
differences were small and not clinically meaningful. Most 
patients were GOLD grade 2 or 3.22
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Table 1 summary of key baseline patient characteristics by matched treatment cohorts and smoking status
Characteristic Initiation sample Step-up sample
Extrafine BDP 
(n=334)
Fluticasone 
(n=334)
P-valuea Extrafine BDP 
(n=189)
Fluticasone 
(n=189)
P-valuea
Male sex, n (%)b 201 (60.2) 201 (60.2) n/a 108 (57.1) 108 (57.1) n/a
age at index date, mean (sD)b 66.5 (8.4) 66.6 (8.1) 0.61 67.2 (8.3) 67.1 (8.6) 0.79
BMI in kg/m2, mean (sD)c 26.4 (5.5) 26.1 (4.7) 0.46 26.5 (5.2) 26.6 (5.5) 0.66
Charlson comorbidity index score, n (%)
 0 205 (61.4) 195 (58.4) 0.48 119 (63.0) 100 (52.9) 0.13
 1 70 (21.0) 67 (20.1) 30 (15.9) 47 (24.9)
 2 28 (8.4) 46 (13.8) 26 (13.8) 21 (11.1)
 $3 31 (9.3) 26 (7.8) 14 (7.4) 21 (11.1)
Current smoker, n (%) 165 (49.7) 162 (48.8) 0.81 75 (39.9) 78 (41.5) 0.74
ex-smoker, n (%) 167 (50.3) 170 (51.2) 113 (60.1) 110 (58.5)
Index prescription date, mean (sD)b 2003.1 (2.3) 2002.8 (2.3) ,0.001 2003.3 (2.2) 2002.7 (2.2) ,0.001
recorded comorbidity, n (%)
 asthma diagnosis 183 (54.8) 187 (56.0) 0.74 141 (74.6) 145 (76.7) 0.63
 rhinitis diagnosis 38 (11.4) 48 (14.4) 0.25 28 (14.8) 31 (16.4) 0.63
 gerD diagnosis 49 (14.7) 54 (16.2) 0.58 26 (13.8) 30 (15.9) 0.56
 Cardiac disease diagnosis 70 (21.0) 45 (13.5) 0.010 45 (23.8) 34 (18.0) 0.15
exacerbations, n (%)b
 0 (COPD treatment success) 131 (39.2) 131 (39.2) n/a 73 (38.6) 73 (38.6) n/a
 1 81 (24.3) 81 (24.3) 33 (17.5) 33 (17.5)
 $2 122 (36.5) 122 (36.5) 83 (43.9) 83 (43.9)
 Patients with $4 exacerbations 39 (11.7) 28 (8.4) – 29 (15.3) 26 (13.8)
recorded %predicted FeV1, n (%) 300 (89.8) 280 (83.8) – 169 (89.4) 163 (86.2) –
 %predicted FeV1, mean (sD) 52.9 (17.9) 52.5 (18.7) 0.90 55.3 (19.3) 52.4 (17.9) 0.21
 %predicted FeV1 ,60%, n (%) 202 (67.3) 193 (68.9) – 101 (59.8) 108 (66.3) –
gOlD grade22,c, n (%)
 gOlD 1 15 (5.4) 19 (7.2) 0.75 12 (7.9) 7 (4.5) 0.12
 gOlD 2 126 (45.5) 109 (41.3) 73 (48.0) 74 (47.7)
 gOlD 3 106 (38.3) 104 (39.4) 51 (33.6) 51 (32.9)
 gOlD 4 30 (10.8) 32 (12.1) 16 (10.5) 23 (14.8)
Baseline therapy, n (%)b
 saBa 154 (46.1) 128 (38.3) 0.027 88 (46.6) 77 (40.7) 0.057
 saMa 22 (6.6) 26 (7.8) 11 (5.8) 5 (2.6)
 saMa + saBa 114 (34.1) 136 (40.7) 35 (18.5) 52 (27.5)
 laBa ± saMa ± saBa 33 (9.9) 33 (9.9) 51 (27.0) 51 (27.0)
 laMa ± saMa ± saBa 7 (2.1) 7 (2.1) 2 (1.1) 2 (1.1)
 laMa + laBa ± saMa ± saBa 1 (0.3) 1 (0.3) 2 (1.1) 2 (1.1)
 Other 3 (0.9) 3 (0.9) 0 0
laBa during baseline year, n (%) 37 (11.1) 35 (10.5) 0.47 53 (28.0) 53 (28.0) n/a
COPD prescriptions, median (IQr) 6 (3–10) 6 (3–11) 0.60 9 (5–13) 10 (6–14) 0.16
Mean daily ICs dose, n (%)b,d
 1–50 µg/d – – n/a 20 (10.6) 11 (5.8) 0.13
 51–100 µg/d – – 47 (24.9) 46 (24.3)
 101–200 µg/d – – 51 (27.0) 60 (31.7)
 201–400 µg/d 51 (27.0) 49 (25.9)
 .400 µg/d – – 20 (10.6) 23 (12.2)
Oral candidiasis,e diagnosis/rx, n (%) 10 (3.0) 11 (3.3) 0.82 10 (5.3) 5 (2.6) 0.15
$1 inpatient admission for COPD/lower  
respiratory condition, n (%)
4 (1.2) 6 (1.8) 0.53 1 (0.5) 1 (0.5) 1.0
antibiotic prescriptions for lrTI, n (%)
 0 prescription 218 (65.3) 216 (64.7) 0.39 123 (65.1) 121 (64.0)
 1 prescription 64 (19.2) 80 (24.0) 37 (19.6) 36 (19.0) 0.67
(Continued)
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Prescribed index date doses of extrafine beclomethasone 
were significantly lower than those of fluticasone (median 
interquartile range [IQR], 200 [200–400] versus 500 [500–
1,000] µg/d; P,0.001; Figure 1).
There were no significant differences between cohorts 
in the unadjusted or adjusted coprimary outcome measures 
(Table 2). Exacerbation rates fell during the 2 year outcome 
period relative to baseline in both cohorts (Figure 2 and 
Table 3); one third of patients in each cohort experienced 
COPD treatment success (no COPD exacerbation during 
the 2 outcome years).
The adjusted odds of treatment stability (no exacer-
bation or treatment change) were significantly better for 
extrafine beclomethasone (adjusted odds ratio [OR], 2.50; 
95% confidence interval [CI], 1.32–4.73), mainly driven by 
significantly lower odds of treatment change in that cohort 
(Table 2). Treatment changes during the outcome period are 
depicted in Figure 3. An increase in ICS dose by $50% was 
significantly more frequent in the extrafine beclomethasone 
cohort, while additional therapy was significantly more fre-
quent in the fluticasone cohort (Table 2). The mean daily ICS 
dose exposure during outcome was significantly lower in the 
extrafine beclomethasone cohort (Table 2 and Figure 4).
A higher percentage of patients in the extrafine beclom-
ethasone cohort had two or more lower respiratory tract 
infections requiring antibiotic therapy (P=0.020), while 
hospitalizations for COPD and lower respiratory conditions 
were infrequent in both cohorts (Table 2). A total of seven 
(2.1%) and four (1.2%) patients in extrafine beclomethasone 
and fluticasone cohorts had a recorded diagnosis of pneu-
monia (P=0.37); we considered the diagnosis confirmed 
for three (0.9%) patients in each cohort. There was no dif-
ference between cohorts in the adjusted odds of developing 
oral candidiasis, experienced by roughly one in ten patients 
(Table 2).
step-up sample
The extrafine beclomethasone and fluticasone cohorts were 
similar at baseline, with mean age of 67 years and 57% male 
(Tables 1 and S3). A significant difference between cohorts 
in index date was small and not clinically meaningful (2003.3 
versus 2002.7; P,0.001).
The stepped-up ICS dose prescribed at the index date 
was significantly lower for extrafine beclomethasone than 
fluticasone (median [IQR] 400 [400–400] versus 1,000 
[500–1,000] µg/d; P,0.001; Figure 1).
Unadjusted and adjusted results for effectiveness mea-
sures were comparable for the two step-up cohorts during 
the 2 year outcome period (Tables 3 and 4). As for the initia-
tion sample, fewer patients in both cohorts experienced $2 
exacerbations/year relative to baseline (Figure 2). Adjusted 
odds of treatment stability and treatment change were similar 
in the two cohorts (Table 4 and Figure 3). Mean daily ICS 
dose exposure was significantly lower for extrafine beclom-
ethasone (Table 4 and Figure 4).
The percentages of patients with lower respiratory tract 
infection requiring antibiotic therapy were similar in the two 
cohorts (Table 4); pneumonia was confirmed for two (1.1%) 
patients in each cohort.
additional analyses
Baseline patient characteristics were broadly similar for 
the matched and full unmatched patient cohorts (Table S4), 
and the unmatched results supported those for the matched 
cohorts (see Supplementary material). In post hoc sensitivity 
analyses, relative ICS doses and exacerbation rates among 
Table 1 (Continued)
Characteristic Initiation sample Step-up sample
Extrafine BDP 
(n=334)
Fluticasone 
(n=334)
P-valuea Extrafine BDP 
(n=189)
Fluticasone 
(n=189)
P-valuea
 $2 prescriptions 52 (15.6) 38 (11.4) 29 (15.3) 32 (16.9)
 all patients with $4 prescriptions 13 (3.9) 5 (1.5) – 3 (1.6) 10 (5.3) –
Notes: aMatched cohorts were compared using conditional logistic regression; bmatching variable (age matching was ±5 years and index prescription date ±1 year for the 
initiation sample and ±2 years for the step-up sample); crecorded BMI data were available for 331 (99%) and 328 (98%) patients in extrafine beclomethasone and fluticasone 
initiation cohorts, respectively, and for 185 (98%) and 184 (97%) patients in extrafine beclomethasone and fluticasone step-up cohorts, respectively. Recorded GOLD severity 
data were available for 277 (83%) and 264 (79%) patients in extrafine beclomethasone and fluticasone initiation cohorts, respectively, and for 152 (80%) and 155 (82%) 
patients in extrafine beclomethasone and fluticasone step-up cohorts, respectively; dthe doses of ICS were standardized to equivalence with extrafine beclomethasone and 
fluticasone; thus, baseline doses of large-particle beclomethasone and budesonide were halved. The daily dose was calculated as the number of days’ supply divided by number 
of prescription days; eoral candidiasis was identified through coded diagnosis or therapy for same, namely, oral antifungal prescriptions.
Abbreviations: BDP, beclomethasone dipropionate; BMI, body mass index; COPD, chronic obstructive pulmonary disease; diagnosis/rx, coded diagnosis or therapy for 
same; FeV1, forced expiratory volume in 1 second; GERD, gastroesophageal reflux disease; GOLD, Global initiative for chronic Obstructive Lung Disease; ICS, inhaled 
corticosteroid; IQr, interquartile range; n/a, not applicable; laBa, long-acting β2-agonist; laMa, long-acting muscarinic antagonist; lrTI, lower respiratory tract infection; 
rx, therapy; saBa, short-acting β2-agonist; saMa, short-acting muscarinic antagonist; sD, standard deviation.
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Figure 1 Daily dose of extrafine beclomethasone and larger-particle fluticasone as prescribed on the index date for (A) the initiation sample and (B) the step-up sample.
Notes: P,0.001 for the differences between cohorts. Percentages may not add up to 100% because of rounding; x-axis not to scale.
Abbreviations: BDP, beclomethasone dipropionate; FP, fluticasone propionate.
unmatched patients without a treatment change during the 
outcome period were similar to findings in the main analyses 
(Tables S5 and S6).
There was no significant difference between the two 
treatment cohorts of initiation or step-up samples in all-cause 
mortality after the outcome period (Table S7).
Discussion
We observed that COPD exacerbation rates in both initiation 
and step-up samples during the 2 year outcome period were 
comparable between matched cohorts prescribed extrafine 
beclomethasone or larger-particle fluticasone in this retro-
spective analysis. For patients initiating ICS for COPD, those 
prescribed extrafine beclomethasone had over twice the odds of 
treatment stability (no COPD exacerbation or treatment change) 
and half the odds of a treatment change. Index date prescribed 
doses of extrafine beclomethasone were significantly lower 
than doses of fluticasone, and the ICS dose exposure during the 
outcome period was significantly lower for both the initiation 
and step-up extrafine beclomethasone cohorts.
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Table 2 Unadjusted and adjusted results during the 2 year outcome period for the matched cohorts of the initiation sample
Outcome Extrafine BDP 
(n=334)
Fluticasone 
(n=334)
Unadjusted odds,  
hazard, or rate  
ratio for extrafine  
BDP (95% CI)
Adjusted odds, 
hazard, or rate 
ratio for extrafine 
BDP (95% CI)
Coprimary outcome measures
 COPD treatment success (0 exacerbations) 118 (35.3) 119 (35.6) Or 0.98 (0.70–1.39) aOr 1.01 (0.70–1.46)b
 exacerbations over 2 years rr 1.05 (0.86–1.30) arr 1.07 (0.87–1.33)c
  0 118 (35.3) 119 (35.6) – –
  1 70 (21.0) 72 (21.6) – –
  2–3 66 (19.8) 83 (24.9) – –
  4–6 49 (14.7) 30 (9.0) – –
  $7 31 (9.3) 30 (9.0) – –
secondary outcome measures
 Time to first exacerbation, median (95% CI), days 419 (315–523) 413 (306–520) hr 1.07 (0.84–1.35) ahr 1.02 (0.79–1.32)d
 Treatment stability (no rx change or additional rx) 66 (19.8) 52 (15.6) Or 1.40 (0.91–2.16) aOr 2.50 (1.32–4.73)e
 Treatment change 183 (54.8) 209 (62.6) Or 0.71 (0.51–0.98) aOr 0.49 (0.32–0.75)f
 Oral candidiasis, diagnosis/rx 28 (8.4) 36 (10.8) rr 1.04 (0.53–2.01) arr 1.06 (0.59–1.90)g
P-valuea
Disaggregated outcome measures
 1 oral corticosteroid course 58 (17.4) 51 (15.3) 0.44 –
 $2 oral corticosteroid courses 56 (16.8) 52 (15.6)
 1 lower respiratory infection + antibiotic rx 69 (20.7) 72 (21.6) 0.020 –
 $2 lower respiratory infections + antibiotic rx 89 (26.6) 63 (18.9)
 $1 hospitalization for COPD or lower respiratory 12 (3.6) 9 (2.7) 0.49 –
Daily ICs dose (µg/d), median (IQr) 315 (151–459) 436 (206–740) ,0.001 –
Daily saBa dose (µg/d), median (IQr) 822 (384–1,534) 918 (384–1,534) 0.22 –
Increase in ICs dose by $50% 96 (28.7) 68 (20.4) 0.017 –
additional new therapy 157 (47.0) 194 (58.1) 0.002 –
Notes: Data are n (%) unless otherwise indicated. Treatment change was defined as the first change and could include an increase in ICS dose and/or additional therapy. 
additional new therapy was new for those patients and could be at any time during the 2 outcome years; patients could have received $1 additional therapy. aConditional 
logistic regression. adjusted for baseline: btheophylline prescriptions and gerD diagnosis and/or therapy; cantibiotics use, laBa, number of primary care consultations, and 
year of first coded diagnosis at practice; drhinitis diagnosis, amitriptyline, antibiotics use, number of COPD prescriptions, and time from first coded diagnosis at practice to 
index date; eyear of index date; fyear of index date and time from first coded diagnosis at practice to index date; gcardiac disease diagnosis, gerD diagnosis and/or therapy, 
number of COPD prescriptions, and oral candidiasis.
Abbreviations: aHR, adjusted hazard ratio; aOR, adjusted odds ratio; aRR, adjusted rate ratio; BDP, beclomethasone dipropionate; CI, confidence interval; COPD, chronic 
obstructive pulmonary disease; diagnosis/rx, coded diagnosis or therapy for same; ICs, inhaled corticosteroid; IQr, interquartile range; rx, treatment; saBa, short-acting 
β2-agonist; OR, odds ratio; HR, hazard ratio; RR, rate ratio; GERD, gastroesophageal reflux disease; LABA, long-acting β2-agonist.
The percentages of patients in each cohort who 
experienced $2 exacerbations/year fell substantially during 
the outcome period. Relative to the baseline year, 11%–13% 
fewer patients in each initiation cohort, and 9%–16% fewer 
in each step-up cohort, experienced $2 exacerbations/year. 
This finding suggests that pharmacotherapy was effective, as 
the experience of frequent COPD exacerbations ($2/year) 
is reportedly a relatively stable patient phenotype.24 These 
 findings suggest, moreover, that increasing the dose of ICS 
can improve outcomes for some patients.  Nonetheless, 
25%–28% of patients in the extrafine beclomethasone cohorts 
and 18%–31% in fluticasone cohorts experienced $4 exac-
erbations during the 2 year outcome period.
Although ICS are not recommended in COPD other than 
in fixed-dose combination with LABA, several studies have 
demonstrated some efficacy of ICS with regard to clinical out-
comes,25 and practice surveys in developed countries indicate 
that prescribing of ICS outside of fixed-dose  combinations 
is not infrequent in usual care.11–13  (Moreover, fluticasone is 
licensed in some countries, including the Netherlands, for 
COPD). In this study, from 40%–49% of patients in initiation 
cohorts and from 33%–35% in step-up cohorts remained on 
ICS monotherapy at the end of the 2 year outcome period, not 
an ideal situation according to guideline recommendations 
but a reality of clinical practice and perhaps a reflection of 
earlier COPD treatment guidelines.
There is little other published work comparing ICS with 
different particle sizes for COPD. Two studies have com-
pared combination ICS/LABA products.26,27 In a 12 week 
double-blind study of 18 patients with lung hyperinflation, 
the combination of extrafine beclomethasone/formoterol, but 
not larger-particle-size fluticasone/salmeterol, was effective 
in reducing air trapping and dyspnea.26 This concurs with our 
findings that the cohort initiating extrafine-particle ICS was 
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Figure 2 Percentage of patients experiencing 0, 1, or ≥2 COPD exacerbations during the baseline year and years 1 and 2 of the 2 year outcome period in (A) the initiation 
sample and (B) the step-up sample.
Abbreviations: COPD, chronic obstructive pulmonary disease; BDP, beclomethasone dipropionate. 
less frequently prescribed a treatment change than the cohort 
initiating larger-particle-size ICS. In another study,  clinical 
outcomes for 232 patients prescribed beclomethasone/for-
moterol were similar to those for 238 patients prescribed 
larger-particle budesonide/formoterol with regard to COPD 
questionnaires and overall low exacerbation rates, while 
FVC improved more in those prescribed beclomethasone/
formoterol.27 The FVC results observed, and those of the prior 
study,26 could perhaps be explained by better  distribution of 
extrafine particles to the small peripheral airways, an impor-
tant site of inflammation in COPD.4,15,16
Further investigations and mechanistic studies are needed 
to explore the comparative effects of differing ICS particle 
sizes for treating COPD, including prospective pragmatic 
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Table 3 exacerbation rates during baseline and outcome periods
Exacerbations Initiation sample Step-up sample
Extrafine BDP 
(n=334)
Fluticasone 
(n=334)
P-valuea Extrafine BDP 
(n=189)
Fluticasone 
(n=189)
P-valuea
Baseline year, mean (sD) 1.4 (1.8) 1.4 (1.8) 0.47 1.7 (2.0) 1.7 (2.0) 1.0
 Median (IQr) 1 (0–2) 1 (0–2) 1 (0–2) 1 (0–2)
Outcome year 1, mean (sD) 1.18 (1.89) 1.07 (1.73) 0.43 1.46 (2.01) 1.31 (1.92) 0.47
 Median (IQr) 0 (0–2) 0 (0–2) 1 (0–2) 1 (0–2)
Outcome year 2, mean (sD) 1.14 (1.90) 1.13 (2.01) 0.95 1.32 (1.91) 1.51 (2.09) 0.33
 Median (IQr) 0 (0–2) 0 (0–1) 1 (0–2) 1 (0–2)
Note: aMatched cohorts were compared using conditional logistic regression.
Abbreviations: BDP, beclomethasone dipropionate; IQr, interquartile range; sD, standard deviation.
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trials of ICS administered concomitantly with long-acting 
bronchodilators. The identification of surrogate markers of 
small airway inflammation evaluable in both smokers and 
ex-smokers would aid this process. Recent work suggests 
that alveolar nitric oxide (NO) is not a useful marker for 
monitoring response to COPD therapy.28
Our composite exacerbation definition included lower 
respiratory tract antibiotic therapy (or an oral corticoster-
oid course or unscheduled hospitalization or ED visit). 
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Figure 3 Changes in treatment and ICs dose during the 2 year outcome period for the (A) extrafine beclomethasone initiation cohort, (B) fluticasone initiation cohort, 
(C) extrafine beclomethasone step-up cohort, (D) fluticasone step-up cohort.
Note: “Other” includes lTra and theophylline.
Abbreviations: BDP, beclomethasone dipropionate; FDC, fixed-dose combination ICS-LABA; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; laMa, long-acting 
muscarinic antagonist; lTra, leukotriene receptor antagonist.
At least one antibiotic prescription for lower respiratory 
tract infection was prescribed during the 2 year follow-up 
for 47% of patients initiating extrafine beclomethasone and 
40% initiating fluticasone, a statistically significant differ-
ence, which may need further study to assess whether this is 
a real observation. Of note, we found the opposite direction 
of effect in the step-up cohorts (although the difference was 
not statistically significant), as 49% and 56% of extrafine 
beclomethasone and fluticasone patients, respectively, 
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Figure 4 Mean daily ICS dose exposure for extrafine beclomethasone and fluticasone cohorts during the 2 year outcome period by (A) the initiation sample and (B) the 
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Notes: P,0.001 for the differences between cohorts. Percentages may not add up to 100% because of rounding. The mean daily dose exposure for each patient was 
calculated as the number of days’ supply divided by 730.
Abbreviations: BDP, beclomethasone dipropionate; FP, fluticasone propionate; ICS, inhaled corticosteroid.
received one or more antibiotic prescriptions. The fact of 
the results being in opposite directions could potentially be 
explained by the distribution of outliers during the baseline 
year, as patients with a higher number of baseline antibiotic 
prescriptions may be more likely to need antibiotic therapy 
during the outcome period: namely, in the initiation sample 
during baseline, 13 patients in the extrafine beclomethasone 
cohort versus five in the fluticasone cohort received from 4–8 
courses of antibiotics; and in the step-up sample  during base-
line, three versus ten, respectively, received from 4–7 courses 
of antibiotics.
In addition to effectiveness of ICS it is important to 
assess side effects.1 Confirmed pneumonia was infrequent 
and comparable with both ICS treatments, recorded for three 
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Table 4 Unadjusted and adjusted results during the 2 year outcome period for the matched cohorts of the step-up sample
Outcome Extrafine BDP 
(n=189)
Fluticasone 
(n=189)
Unadjusted odds,  
hazard, or rate  
ratio for extrafine  
BDP (95% CI)
Adjusted odds, 
hazard, or rate 
ratio for extrafine 
BDP (95% CI)
Coprimary outcome measures
 COPD treatment success (0 exacerbations) 58 (30.7) 50 (26.5) Or 1.33 (0.79–2.26) aOr 1.45 (0.70–3.00)b
 exacerbations over 2 years rr 0.98 (0.78–1.24) arr 0.98 (0.79–1.23)c
  0 58 (30.7) 50 (26.5) – –
  1 32 (16.9) 36 (19.0) – –
  2–3 47 (24.9) 44 (23.3) – –
  4–6 27 (14.3) 40 (21.2) – –
  $7 25 (13.2) 19 (10.1) – –
secondary outcome measures
 Time to first exacerbation, median (95% CI), days 313 (222–404) 289 (192–386) hr 0.96 (0.71–1.31) ahr 0.97 (0.70–1.34)d
 Treatment stability (no rx change or additional rx) 36 (19.0) 25 (13.2) Or 1.65 (0.90–3.01) aOr 1.68 (0.78–3.59)e
 Treatment change 102 (54.0) 111 (58.7) Or 0.84 (0.57–1.24) aOr 0.75 (0.48–1.18)f
 Oral candidiasis, diagnosis/rx 17 (9.0) 19 (10.1) rr 1.96 (0.83–4.62) arr 1.06 (0.54–2.06)g
P-valuea
Disaggregated outcome measures
 1 oral corticosteroid course 24 (12.7) 32 (16.9) 0.71 –
 $2 oral corticosteroid courses 51 (27.0) 50 (26.5)
 1 lower respiratory infection + antibiotic rx 46 (24.3) 53 (28.0) 0.22 –
 $2 lower respiratory infections + antibiotic rx 46 (24.3) 52 (27.5)
 $1 hospitalization for COPD or lower respiratory 8 (4.2) 3 (1.6) 0.15 –
Daily ICs dose (µg/d), median (IQr) 438 (274–619) 534 (329–843) ,0.001 –
Daily saBa dose (µg/d), median (IQr) 1,041 (548–1,671) 1,096 (493–1,808) 0.29 –
Increase in ICs dose by $50% 28 (14.8) 21 (11.1) 0.28 –
additional new therapy 100 (52.9) 105 (55.6) 0.62 –
Notes: Data are n (%) unless otherwise indicated. Treatment change was defined as the first change and could include an increase in ICS dose and/or additional therapy. 
additional new therapy was new for those patients and could be at any time during the 2 outcome years; patients could have received $1 additional therapy. aConditional 
logistic regression. adjusted for baseline: badherence to ICS therapy, number of primary care consultations, and time from first coding of COPD at practice to index date; 
cadherence to ICs therapy and no primary care consultations; dnumber of primary care consultations; egerD diagnosis and/or therapy and adherence to ICs; fgerD diagnosis 
and/or therapy and adherence to ICs; gbeta blockers, gerD diagnosis and/or therapy, adherence to ICs therapy, and oral candidiasis.
Abbreviations: aHR, adjusted hazard ratio; aOR, adjusted odds ratio; aRR, adjusted rate ratio; BDP, beclomethasone dipropionate; CI, confidence interval; COPD, chronic 
obstructive pulmonary disease; diagnosis/Rx, coded diagnosis or therapy for same; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; Rx, treatment; SABA, 
short-acting β2-agonist; IQr, interquartile range; Or, odds ratio; hr, hazard ratio; rr, rate ratio.
patients in each initiation cohort and one in each step-up 
cohort. However, the incidence of pneumonia may have been 
underestimated in this study, as some cases of pneumonia 
may have been coded as lower respiratory tract infection 
and treated in the home setting. Moreover, it is possible that 
some hospitalizations for pneumonia were not captured in 
the database. The post-study all-cause mortality rates did not 
differ between cohorts.
Observational research provides important insights into 
the realities of real-life practice. For instance, although 
extrafine beclomethasone is not approved for use in COPD, 
this analysis shows that it is widely prescribed for patients 
with COPD in general practice. The effectiveness and safety 
information provided in this analysis for patients with COPD 
prescribed extrafine beclomethasone is a novel and valuable 
addition to the literature. Observational research also enables 
the study of heterogeneous patient populations in real-life 
clinical care conditions, providing relevant information 
to complement that from tightly controlled and selective 
randomized clinical trials.29,30 This matched cohort study 
included a broad range of patients who were prescribed 
COPD therapy under usual conditions of care in UK gen-
eral practice. The fact that baseline patient characteristics 
were broadly similar for matched and unmatched patient 
groups suggests that studied patients were representative 
of the general UK COPD population. The inclusive patient 
population enhances external validity of findings and their 
generalizability to real-life practice. In addition, we followed 
patients for 2 years, allowing us to describe the course of 
therapy over this time period.
A high percentage of patients in this study, $55% in each 
treatment cohort, also had a diagnosis of asthma recorded in 
the database (after the age of 40, per inclusion criteria). This 
may reflect the fact that a subgroup of patients with asthma 
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develops persistent airway obstruction over time, particularly 
when they smoke.31 We believe that the COPD diagnosis was 
valid for most patients under study for several reasons: 1) all 
patients had a recorded post-bronchodilator FEV
1
/FVC ratio 
of ,0.7; 2) all were smokers or ex-smokers; 3) the mean age 
was 67 years, and the cohorts included a preponderance of 
men (60%); 4) among those with an FEV
1
 reading at baseline 
(87% of the full population studied), the mean %predicted 
FEV
1
 in the four cohorts ranged from 52% to 55% (depending 
on cohort); and from 60% to 69% of patients in each cohort 
had a %predicted FEV
1
 of ,60%; 5) moreover, of the patients 
with an asthma codiagnosis, most also had substantial FEV
1
 
impairment (mean FEV
1
 %predicted, 53%; data not shown); 
6) finally, the COPD diagnosis was recorded at or close to 
the time of the asthma diagnosis for most patients, and, 
importantly, the COPD diagnosis was confirmed (via FEV
1
/
FVC ratio ,0.7) for most patients after the asthma diagno-
sis was recorded (Figure S3). This suggests that the asthma 
codiagnosis was often an initial misdiagnosis that was later 
superseded by a diagnosis of COPD.
Retrospective studies such as this one are limited by the 
available data. All included patients had a database-recorded 
post-bronchodilator FEV
1
/FVC ,0.7; however, we were 
unable to track lung function during the outcome period 
because spirometry is not performed routinely in primary 
care. Moreover, not all potential matching criteria were avail-
able for all patients at baseline, including the FEV
1
 value 
(hence GOLD grade) and scores for the modified Medical 
Research Council or COPD Assessment Test, which would 
have enabled patient categorization according to recent 
GOLD guidelines.1 Nonetheless, patients appeared to be 
well-matched for physical characteristics and disease sever-
ity, and the analyses incorporated adjustments for residual 
confounding (although we cannot rule out unidentified con-
founding factors). Finally, the percentages of patients in each 
cohort who quit smoking during the outcome period would 
have been of interest, since the effects of ICS can be less in 
smokers with COPD.
Conclusion
This study has enabled us to describe the use of ICS for 
patients with COPD in UK primary care. We observed that 
ICS are prescribed, both as monotherapy and in combination 
with long-acting bronchodilators, for treating COPD and 
can result in improved exacerbation rates as in our COPD 
patients with predominantly GOLD grade 2 and 3 severity 
of airflow limitation. Our observations that small-particle 
ICS at significantly lower doses had the same effects as 
larger-particle ICS at higher doses and that small-particle 
ICS use was associated with greater odds of treatment sta-
bility and lower odds of treatment change during the 2 year’ 
follow-up could be explained by greater lung deposition, 
especially to the small airways. Future pragmatic trials are 
needed to prospectively evaluate the effectiveness of ICS of 
differing particle sizes in COPD, administered concomitantly 
with long-acting bronchodilators.
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Supplementary materials
results for unmatched patient 
populations
• For the unmatched patients: prescribed inhaled corti-
costeroids doses were significantly lower for extrafine 
beclomethasone in both
 ○  initiation sample: median interquartile range [IQR], 
200 [200–400] versus fluticasone 500 [500–1000] µg/d; 
P,0.001, and
 ○  step-up sample: median [IQR], 400 [400–400] versus 
fluticasone 1,000 [500–1,000] µg/d; P,0.001.
• For the unmatched patients: primary outcome measures 
showed no significant difference between cohorts in 
COPD exacerbation rate during outcome, with adjusted 
rate ratio
 ○  for initiation sample: 1.04 (95% confidence interval 
[CI], 0.89–1.22) for extrafine beclomethasone relative 
to fluticasone
 ○  step-up sample: 0.94 (95% CI, 0.80–1.10) for extrafine 
beclomethasone.
• For the unmatched patients: there was no significant 
difference between cohorts in odds of COPD treatment 
success during outcome, with adjusted odds ratio 
 ○  for initiation sample: 0.99 (95% CI, 0.77–1.29) for 
extrafine beclomethasone relative to fluticasone
 ○  step-up sample: odds ratio 1.20 (95% CI, 0.83–1.72) 
for extrafine beclomethasone.
Table S1 Chronic respiratory diseases and database codes that 
were cause for study exclusion
NHS read code NHS read term
aD5..00 sarcoidosis
h4...00 lung disease due to external agents
h4...11 Pneumoconiosis
h4...12 Occupational lung disease
h40..00 Coal workers’ pneumoconiosis
h41..00 asbestosis
h410.00 Pleural plaque disease/asbestosis
h41z.00 asbestosis nOs
h42..00 silica/silicate pneumoconiosis
h420.00 Talc pneumoconiosis
h421.00 simple silicosis
h422.00 Complicated silicosis
h423.00 Massive silicotic fibrosis
h42z.00 silica pneumoconiosis nOs
h43..00 Pneumoconiosis-other inorganic dust
h431.00 Bauxite fibrosis of lung
h432.00 Berylliosis
h433.00 Graphite fibrosis of lung
h434.00 siderosis
h435.00 stannosis
h43z.00 Pneumoconiosis-inorganic dust nOs
h44..00 Pneumopathy-other dust inhalation
h440.00 Byssinosis
h441.00 Cannabinosis
h44z.00 Pneumopathy-dust inhalation nOs
h45..00 Pneumoconiosis nOs
h450.00 Pneumoconiosis associated with tuberculosis
h46..00 respiratory disease – chemical fumes
h460.00 Chemical bronchitis/pneumonitis
h460z00 Chemical bronchitis/pneumonitis nOs
h464.00 Chronic chemical respiratory conditition
h464100 Chemical obliterative bronchiolitis
h464200 Chemical pulmonary fibrosis
h464z00 Chronic chemical respiratory condition nOs
h46z.00 Chemical respiratory conditions nOs
h46zz00 Chemical respiratory conditions nOs
h48..00 Progressive massive fibrosis
h4y..00 external agent lung disease Os
h4y1.00 Chronic pulmonary radiation disease
h4y1000 Radiation pulmonary fibrosis
h4y1z00 Chronic pulmonary radiation disease nOs
h4y2.00 Drug-induced interstitial lung disorder
h4y2100 Chronic drug-induced interstitial lung disorder
h4yy.00 Other external agent respiratory condition
h4yz.00 external agent respiratory condition nOs
h4z..00 external agent lung disease nOs
h57y200 Pulmonary sarcoidosis
Abbreviations: NHS, National Health Service; NOS, not otherwise specified; 
Os, otherwise stated.
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Table S2 list of potential confounding variables considered for 
this study
•  The index date
Potential confounders examined at (or closest to) the relevant 
index date
•  age
•  sex
•  height
•  Weight
•  Body mass index
•  lung function, in terms of spirometry before index date
•  smoking status
Potential confounders examined regardless of when they 
occurred relative to the index date
•  Date of first COPD diagnosis (where known)
•  Other respiratory or other confounding diagnoses, including rhinitis, 
gastroesophageal reflux disease, and cardiac disease
Potential confounders examined in the year before 
the index date
•  Other important unrelated comorbidities expressed using the 
Charlson Comorbidity Index, calculated over the 1 year baseline 
period
•  number of general practice consultations for COPD or other 
respiratory illness
•  number of hospital outpatient attendances where COPD is recorded 
as the reason for referral
•  number of hospitalizations or emergency department attendance for 
COPD or possibly respiratory-related (a non-specific hospitalization 
code and a COPD/respiratory code within a 1 week window)
•  number of acute courses of oral corticosteroids
•  number of prescriptions for any antibiotic where the reason for the 
prescription is lower respiratory tract infection
•  Other medications that might interfere with COPD control, including 
beta-blockers, nsaIDs, acetaminophen, and antidepressants
•  Prior treatment classified as
 ○  no drug therapy
 ○  saBa only
 ○  saMa ± saBa
 ○  laBa ± saMa ± saBa
 ○  laMa ± saMa ± saBa
 ○  laMa ± laBa ± saMa ± saBa
•  average ICs daily dose during baseline year
Abbreviations: COPD, chronic obstructive pulmonary disease; ICs, inhaled 
corticosteroid; laBa, long-acting β2-agonist; laMa, long-acting muscarinic 
antagonist; NSAID, nonsteroidal anti-inflammatory drug; SABA, short-acting 
β2-agonist; saMa, short-acting muscarinic antagonist.
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Table S3 additional baseline patient characteristics by matched treatment cohort
Characteristic Initiation sample Step-up sample
Extrafine BDP 
(n=334)
Fluticasone 
(n=334)
P-valuea Extrafine BDP 
(n=189)
Fluticasone 
(n=189)
P-valuea
Timing of COPD diagnosis code in database, n (%)
 .3 yr before index date 52 (15.6) 63 (18.9) 0.13 50 (26.5) 57 (30.2) 0.17
 6 mo to 3 yr before index date 82 (24.6) 81 (24.3) 32 (16.9) 43 (22.8)
 at or ,6 mo before index date 102 (30.5) 117 (35.0) 33 (17.5) 28 (14.8)
 ,3 yr after index date 66 (19.8) 40 (12.0) 41 (21.7) 31 (16.4)
 $3 yr after index date 32 (9.6) 33 (9.9) 33 (17.5) 30 (15.9)
BMI category, n (%)b
 Underweight (BMI ,18.5 kg/m2) 14 (4.2) 15 (4.6) 0.96 5 (2.7) 6 (3.3) 0.84
 normal (BMI 18.5–,24.5 kg/m2) 132 (39.9) 125 (38.1) 75 (40.5) 78 (42.4)
 Overweight (BMI 24.5–,30 kg/m2) 115 (34.7) 121 (36.9) 67 (36.2) 57 (31.0)
 Obese (BMI $30 kg/m2) 70 (21.1) 67 (20.4) 38 (20.5) 43 (23.4)
$1 prescription in baseline year or at index date, n (%)
 Beta blocker 37 (11.1) 35 (10.5) 0.80 19 (10.1) 9 (4.8) 0.056
 nsaID 134 (40.1) 113 (33.8) 0.082 81 (42.9) 70 (37.0) 0.26
 Paracetamol 114 (34.1) 123 (36.8) 0.47 75 (39.7) 72 (38.1) 0.72
 antidepressant 47 (14.1) 65 (19.5) 0.049 35 (18.5) 27 (14.3) 0.11
Daily saBa dose, median (IQr) 219 (110–548) 219 (110–548) 0.77 384 (219–658) 438 (219–767) 0.22
Daily saMa dose, median (IQr) 0 (0–55) 11 (0–55) 0.16 0 (0–44) 0 (0–55) 0.40
Pneumonia diagnosis, confirmed, n (%) 0 (0) 3 (0.9) n/a 1 (0.5) 0 (0) n/a
Notes: aMatched cohorts were compared using conditional logistic regression; brecorded BMI data were available for 331 (99%) and 328 (98%) patients in extrafine 
beclomethasone and fluticasone initiation cohorts, respectively, and for 185 (98%) and 184 (97%) patients in extrafine beclomethasone and fluticasone step-up cohorts, 
respectively.
Abbreviations: BDP, beclomethasone dipropionate; BMI, body mass index; COPD, chronic obstructive pulmonary disease; IQr, interquartile range; n/a, not applicable; 
NSAID, nonsteroidal anti-inflammatory drug; SABA, short-acting β2-agonist; saMa, short-acting muscarinic antagonist; yr, years; mo, months.
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Table S4 Baseline characteristics of unmatched cohorts
Characteristic Initiation – unmatched Step-up – unmatched
Extrafine BDP  
(n=938)
Fluticasone  
(n=443)
Extrafine BDP  
(n=372)
Fluticasone 
(n=606)
Male sex, n (%)a 535 (57.0) 259 (58.5) 206 (55.4) 325 (53.6)
age at index date, mean (sD)a 67.5 (9.5) 65.6 (8.8) 67.8 (10.1) 65.2 (9.5)
BMI in kg/m2, mean (sD) 26.1 (5.2) 26.2 (4.8) 26.6 (5.2) 26.3 (5.3)
Charlson comorbidity index score, n (%)
 0 577 (61.5) 268 (60.5) 236 (63.4) 360 (59.4)
 1 197 (21) 84 (19) 58 (15.6) 121 (20.0)
 2 96 (10.2) 58 (13.1) 50 (13.4) 70 (11.6)
 $3 68 (7.2) 33 (7.4) 28 (7.5) 55 (9.1)
Current smoker, n (%) 422 (46.1) 209 (48.2) 141 (39.1) 267 (45.9)
ex-smoker, n (%) 494 (53.9) 225 (51.8) 220 (60.9) 315 (54.1)
Index prescription date, mean (sD)a 2004.4 (2.4) 2002.3 (2.6) 2004.2 (2.3) 2001.3 (2.8)
recorded comorbidity, n (%)
 asthma diagnosis 479 (51.1) 261 (58.9) 264 (71.0) 477 (78.7)
 rhinitis diagnosis 116 (12.4) 66 (14.9) 47 (12.6) 98 (16.2)
 gerD diagnosis 145 (15.5) 70 (15.8) 47 (12.6) 121 (20.0)
 Cardiac disease diagnosis 186 (19.8) 58 (13.1) 74 (19.9) 111 (18.3)
exacerbations, n (%)b
 0 (COPD treatment success) 345 (36.8) 172 (38.8) 145 (39.0) 215 (35.5)
 1 251 (26.8) 113 (25.5) 93 (25.0) 137 (22.6)
 $2 342 (36.5) 158 (35.7) 134 (36.0) 254 (41.9)
recorded %predicted FeV1, n (%) 835 (89.0) 374 (84.4) 341 (91.7) 517 (85.3)
 %predicted FeV1, mean (sD) 55.3 (18.5) 52.0 (18.9) 56.3 (19.9) 49.5 (18.7)
gOlD grade (2008 criteria), n (%)
 gOlD 1 78 (9.1) 33 (8.5) 44 (12.7) 35 (6.7)
 gOlD 2 431 (50.1) 161 (41.6) 168 (48.4) 198 (37.6)
 gOlD 3 280 (32.5) 139 (35.9) 105 (30.3) 209 (39.7)
 gOlD 4 72 (8.4) 54 (14.0) 30 (8.6) 84 (16.0)
Baseline therapy, n (%)a
 saBa 56 (6.0) 30 (6.8) 148 (39.8) 198 (32.7)
 saMa 308 (32.8) 155 (35.0) 17 (4.6) 12 (2.0)
 saMa + saBa 72 (7.7) 76 (17.2) 66 (17.7) 126 (20.8)
 laBa ± saMa ± saBa 47 (5.0) 14 (3.2) 86 (23.1) 223 (36.8)
 laMa ± saMa ± saBa 11 (1.2) 4 (0.9) 21 (5.6) 7 (1.2)
 laMa + laBa ± saMa ± saBa 15 (1.6) 11 (2.5) 23 (6.2) 19 (3.1)
 Other 94 (10.0) 84 (19.0) 11 (3.0) 21 (3.5)
laBa during baseline year, n (%) 6 (3–10) 5 (3–11) 110 (29.6) 247 (40.8)
COPD prescriptions, median (IQr) 56 (6.0) 30 (6.8) 9 (5–13) 10 (6–14)
Mean daily ICs dose, n (%)a,b n/a n/a
 1–50 µg/d n/a n/a 29 (7.8) 26 (4.3)
 51–100 µg/d n/a n/a 82 (22.0) 89 (14.7)
 101–200 µg/d n/a n/a 115 (30.9) 170 (28.1)
 201–400 µg/d n/a n/a 106 (28.5) 156 (25.7)
 .400 µg/d n/a n/a 40 (10.8) 165 (27.2)
Oral candidiasis, diagnosis/rx, n (%) 16 (1.7) 12 (2.7) 18 (4.8) 38 (6.3)
$1 Inpatient admission for COPD/lower  
respiratory condition, n (%)
13 (1.4) 9 (2.0) 4 (1.1) 11 (1.8)
antibiotics: 1 prescription, n (%) 206 (22.0) 103 (23.3) 81 (21.8) 125 (20.6)
  $2 prescriptions, n (%) 155 (16.5) 49 (11.1) 51 (13.7) 99 (16.3)
Daily saBa dose, median (IQr) 219 (110–548) 219 (110–548) 438 (164–712) 493 (219–877)
Daily saMa dose, median (IQr) 0 (0–44) 11 (0–55) 0 (0–44) 0 (0–66)
Pneumonia diagnosis, confirmed, n (%) 5 (0.5) 3 (0.7) 1 (0.3) 3 (0.5)
Notes: aMatching variable (age matching was ±5 years and index prescription date ±1 year for the initiation population and ±2 years for the step-up population); bthe doses 
of ICS were standardized to equivalence with extrafine beclomethasone and fluticasone; thus, baseline doses of large-particle beclomethasone and budesonide were halved. 
The daily dose was calculated as the number of days’ supply divided by number of prescription days.
Abbreviations: BDP, beclomethasone dipropionate; BMI, body mass index; COPD, chronic obstructive pulmonary disease; diagnosis/rx, coded diagnosis or therapy for 
same; FeV1, forced expiratory volume in 1 second; GERD, gastroesophageal reflux disease; GOLD, Global initiative for chronic Obstructive Lung Disease; ICS, inhaled 
corticosteroid; IQr, interquartile range; n/a, not applicable; laBa, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; NSAID, nonsteroidal anti-inflammatory 
drug; saBa, short-acting β2-agonist; saMa, short-acting muscarinic antagonist; sD, standard deviation.
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Table S5 results during the 2 year outcome period for the initiation sample, unmatched cohorts, no treatment change
Outcome Extrafine BDP 
(n=413)
Fluticasone 
(n=180)
Adjusted odds, hazard, or rate 
ratio for extrafine BDP (95% CI)
Coprimary outcome measures
 COPD treatment success (0 exacerbations) 170 (41.2) 79 (43.9) Or 0.93 (0.64–1.37)b
 exacerbations over 2 years rr 0.89 (0.66–1.20)c
  0 170 (41.2) 79 (43.9)
  1 98 (23.7) 40 (22.2)
  2–3 83 (20.1) 36 (20.0)
  4–6 46 (11.1) 8 (4.4)
  $7 16 (3.9) 17 (9.4)
secondary outcome measures
 Time to first exacerbation, median (95% CI), days hr 1.05 (0.82–1.34)d
P-valuea
Disaggregated outcome measures
 1 oral corticosteroid course 53 (12.8) 22 (12.2) 0.75
 $2 oral corticosteroid courses 42 (10.2) 15 (8.3)
 1 lower respiratory infection + antibiotic rx 86 (20.8) 35 (19.4) 0.68
 $2 lower respiratory infections + antibiotic rx 76 (18.4) 29 (16.1)
 $1 hospitalization for COPD or lower respiratory 3 (0.7) 1 (0.6) 0.82
Daily ICs dose (µg/d), median (IQr) 219 (110–356) 390 (138–740) ,0.001
Daily saBa dose (µg/d), median (IQr) 712 (329–1,315) 712 (274–1,452) 0.70
Increase in ICs dose by $50% 43 (10.4) 18 (10.0) 0.88
Continuing laBa from baseline 53 (12.8) 46 (25.6)
Confirmed pneumonia diagnosis 1 (0.2) 1 (0.6) not applicable
Notes: Data are n (%) unless otherwise indicated. aConditional logistic regression. adjusted for baseline: badjusted for: age, antibiotics use (with a lower respiratory read code 
within a ±5 day window) (categorized), prescriptions for theophylline (Yes/No) and time between first coded diagnosis at practice and the index date (categorized); cadjusted 
for: age, rhinitis diagnosis (Yes/no), antibiotics use (with a lower respiratory read code within a ±5 day window) (categorized), acute use of oral steroids (categorized), 
number of lower respiratory-related consultations (categorized), beta blockers (Yes/No), prescriptions for theophylline (Yes/No) and Year of first coded diagnosis at practice 
(categorized); dadjusted for: age, antibiotics use (with a lower respiratory read code within a ±5 day window) (categorized), number of COPD consultations (categorized), 
prescriptions for theophylline (Yes/no) and inpatient admissions for COPD (Yes/no).
Abbreviations: HR, hazard ratio; OR, odds ratio; RR, rate ratio; BDP, beclomethasone dipropionate; CI, confidence interval; COPD, chronic obstructive pulmonary disease; 
ICs, inhaled corticosteroid; IQr, interquartile range; laBa, long-acting β2-agonist; rx, treatment; saBa, short-acting β2-agonist.
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Table S6 Unadjusted and adjusted results during the 2 year outcome period for the step-up sample, unmatched cohorts, no treatment 
change
Outcome Extrafine BDP 
(n=178)
Fluticasone 
(n=240)
Adjusted odds, hazard, or rate 
ratio for extrafine BDP (95% CI)
Coprimary outcome measures
 COPD treatment success (0 exacerbations) 65 (36.5) 86 (35.8) Or 0.80 (0.50–1.29)b
 exacerbations over 2 years rr 0.97 (0.74–1.26)c
  0 65 (36.5) 86 (35.8)
  1 43 (24.2) 37 (15.4)
  2–3 39 (21.9) 55 (22.9)
  4–6 19 (10.7) 37 (15.4)
  $7 12 (6.7) 25 (10.4)
secondary outcome measures
 Time to first exacerbation, median (95% CI), days hr 1.10 (0.85–1.42)d
P-valuea
Disaggregated outcome measures
 1 oral corticosteroid course 27 (15.2) 37 (15.4) 0.005
 $2 oral corticosteroid courses 26 (14.6) 66 (27.5)
 1 lower respiratory infection + antibiotic rx 48 (27.0) 46 (19.2) 0.091
 $2 lower respiratory infections + antibiotic rx 29 (16.3) 54 (22.5)
 $1 hospitalization for COPD or lower respiratory 7 (3.9) 3 (1.3) 0.076
Daily ICs dose (µg/d), median (IQr) 411 (219–575) 740 (432–1,027) ,0.001
Daily saBa dose (µg/d), median (IQr) 822 (329–1,315) 1,096 (438–1,781) 0.002
Increase in ICs dose by $50% 4 (2.2) 12 (5.0) 0.15
Continuing laBa from baseline 61 (34.3) 121 (50.4) 0.001
Confirmed pneumonia diagnosis 2 (1.1) 2 (0.8) 0.76
Notes: Data are n (%) unless otherwise indicated. aConditional logistic regression. adjusted for baseline: badjusted for: asthma diagnosis (Yes/no), gerD diagnosis and/or 
therapy (Yes/no), cardiac disease diagnosis and/or therapy (Yes/no), acute use of oral steroids (categorized), number of primary care consultations (categorized), prior 
LABA use (Yes/No) and time between first coded diagnosis at practice and the index date (categorized); cadjusted for: antibiotics use (with a lower respiratory read 
code within a ±5 day window) (categorized), acute use of oral steroids (categorized), number of COPD consultations (categorized), average daily ICs dose (categorized), 
prescriptions for paracetamol (Yes/No), prior LABA use (Yes/No) and time between first coded diagnosis at practice and IPD (categorized); dadjusted for: gerD diagnosis 
and/or therapy (Yes/no), antibiotics use (with a lower respiratory read code within a ±5 day window) (categorized 0–1/2+ to meet proportional hazards requirement), acute 
use of oral steroids (categorized 0–1/2+ to meet proportional hazards requirement), prior laBa use (Yes/no) and number of primary care consultations (categorized).
Abbreviations: HR, hazard ratio; OR, odds ratio; RR, rate ratio; BDP, beclomethasone dipropionate; CI, confidence interval; COPD, chronic obstructive pulmonary disease; 
GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β2-agonist; rx, treatment; saBa, short-acting β2-agonist.
Table S7 Post-study mortality rates
Initiation sample Step-up sample
Extrafine BDP 
(n=334)
Fluticasone 
(n=334)
Extrafine BDP 
(n=189)
Fluticasone 
(n=189)
Follow-up time in yearsa mean (sD) 6.6 (2.5) 7.0 (2.6) 6.4 (2.3) 7.2 (2.3)
number of deaths, n (%) 58 (17.4) 64 (19.2) 26 (13.8) 39 (20.6)
all-cause mortality, adjusted hr (95% CI) 1.07 (0.68–1.70)b 1.00 1.23 (0.61–2.47)c 1.00
Notes: The study was not designed to evaluate mortality rates during treatment, as patients had to be alive throughout the 2 year outcome period to be eligible for the 
study. aFollow-up time from index date until censored or the end of the study period (end of 2010). Cox proportional hazards model: badjusted for Charlson comorbidity 
index score and smoking status; cadjusted for age and cardiac disease diagnosis or therapy.
Abbreviations: BDP, beclomethasone dipropionate; CI, confidence interval; HR, hazard ratio; SD, standard deviation.
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Total matched patients included
Extrafine beclomethasone n=334
Fluticasone n=334
1:1 uniquely matched pairs: n=489
-Year of index date ±1 year
Extrafine beclomethasone n=1,454
Fluticasone n=818
-Same sex
-Age ±5 years
-Baseline year no COPD
 exacerbations (0, 1, ≥2)
-Baseline Rx: (a) SABA/SAMA/
 SABA + SAMA, (b) LABA,
(c) LAMA, (d) LABA+LAMA±SABA
±SAMA, or (e) other
*Software used to randomly pick
unique matched patients
Randomize matching patients 1:1*
Patients with COPD initiating
ICS therapy as:
Patients prescribed
beclomethasone or fluticasone
n=35,487
Excluded
Excluded
Inclusion criteria
Matching criteria applied
Patients on ICS at any time post-1990
± long-acting anticholinergic
Patients prescribed
any ICS inhalers
n=696,489
± theophylline
± ipratropium/salbutamol
Respiratory patients
in the GPRD and OPCRD
n=1,515,507
-No recorded COPD diagnosis (n=588,951)
Patients not on any ICS therapy
(n=819,018)
-Started on ICS before 1997 (n=36,935)
-Started ICS at age <40 years (n=2,028)
-Other chronic respiratory disease (n=897)
-Started on DPI, BAI, budesonide, or
 ciclesonide (n=17,866)
-Prescribed an FDC ICS-LABA (n=1,235)
-Not registered at practice for 1 year before and
 2 years after index date (n=13,090)
Extrafine beclomethasone n=529
Extrafine beclomethasone n=436
-<2 COPD Rx baseline year (n=20,496)
-Duplicated in GPRD and OPCRD (n=1,428)
-FEV1/FVC ratio >0.7 (n=1,466)
-On large-particle beclomethasone (n=9,825)
Fluticasone n=55
Fluticasone n=274
Double matches lost on
randomisation 1:1
Lost on matching
Excluded
-Non-smokers (n=20)
-Asthma diagnosis at <40 years old
 (n=1)
Excluded pairs
-COPD not confirmed by spirometry
  (n=134)
Figure S1 Patient selection and matching for the initiation sample.
Note: Patients in the two treatment cohorts were matched on clinically and demographically significant characteristics.
Abbreviations: BAI, breath-actuated inhaler; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FDC, fixed-dose combination; FEV1, forced expiratory 
volume in 1 second; FVC, forced vital capacity; gPrD, general Practice research Database; ICs, inhaled corticosteroid; laBa, long-acting β2-agonist; laMa, long-acting 
muscarinic antagonist; OPCrD, Optimum Patient Care research Database; rx, therapy; saBa, short-acting β2-agonist; saMa, short-acting muscarinic antagonist.
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Total matched patients included
Extrafine beclomethasone n=189
Fluticasone n=189
1:1 uniquely matched pairs: n=252
-Year of index date ±1 years
-Baseline year mean ICS dose
      (0–250, 251–500, >500 µg/d)
Extrafine beclomethasone n=629
Fluticasone n=1,268
-Same sex
-Age ±5 years
-Baseline year no COPD
 exacerbations (0, 1, ≥2)
-Baseline Rx: (a) SABA/SAMA/
 SABA + SAMA, (b) LABA, 
(c) LAMA, (d) LABA + LAMA ±
SABA ± SAMA, or (e) other
 
 
*Software used to randomly pick
unique matched patients
Randomize matching patients 1:1*
Patients with COPD initiating
ICS therapy as
Patients prescribed
beclomethasone or fluticasone
n=9,283
Excluded
Excluded
Inclusion criteria
Matching criteria applied
Patients on ICS at any time post-1990
± long-acting anticholinergic
Patients prescribed
any ICS inhalers
n=696,489
± theophylline
± ipratropium/salbutamol
Respiratory patients
in the GPRD and OPCRD
n=1,515,507
-No recorded COPD diagnosis (n=93,249)
-No further ICS therapy (n=114,045)
-No increase in ICS dose ever (n=383,753)
-Started on DPI, BAI, budesonide, or ciclesonide
  or first increase via DPI or BAI (n=81,480)
Patients not on any ICS therapy
(n=819,018)
-Started on ICS before 1997 (n=8,708)
-Started ICS at age <40 years (n=328)
-Other chronic respiratory disease (n=254)
-Prescribed an FDC ICS-LABA in baseline
 (n=163)
-Multiple ICS in baseline year (n=137)
-Not registered at practice for 1 year before and 
 2 years after index date (n=5,089)
Extrafine beclomethasone n=54
Extrafine beclomethasone n=306
-Multiple ICS or FDC prescribed at index
  date (n=298)
-Duplicated in GPRD and OPCRD (n=830)
-FEV1/FVC ratio >0.7 (n=656)
-<2 COPD Rx baseline year (n=1,693)
-On large-particle beclomethasone (n=3,909)
Fluticasone n=643
Fluticasone n=895
Double matches lost on
randomisation 1:1
Lost on matching
Excluded
-Non-smokers (n=6)
-Asthma diagnosis at <40 years old
 (n=5)
Excluded pairs:
-COPD not confirmed by spirometry
  (n=52)
Figure S2 Patient selection and matching for the step-up sample.
Abbreviations: BAI, breath-actuated inhaler; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FDC, fixed-dose combination; FEV1, forced expiratory 
volume in 1 second; FVC, forced vital capacity; gPrD, general Practice research Database; ICs, inhaled corticosteroid; laBa, long-acting β2-agonist; laMa, long-acting 
muscarinic antagonist; OPCrD, Optimum Patient Care research Database; rx, therapy; saBa, short-acting β2-agonist; saMa, short-acting muscarinic antagonist.
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Figure S3 Time plots of the COPD diagnosis showing (A) the time of the COPD 
diagnosis relative to time of first asthma diagnosis for the full unmatched population 
who also had a recorded asthma diagnosis, and (B) the time of the COPD 
confirmation (by FEV1/FVC ratio ,0.7) relative to time of the asthma diagnosis for 
these patients.
Abbreviations: COPD, chronic obstructive pulmonary disease; dx, diagnosis; 
sD, standard deviation; FeV1, forced expiratory volume in 1 second; FVC, forced 
vital capacity.
